Market Closed -
Nasdaq
04:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
6.34
USD
|
+0.63%
|
|
-3.21%
|
-29.48%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
610
|
1,391
|
1,900
|
1,350
|
675.6
|
482.7
|
-
|
-
|
Enterprise Value (EV)
1 |
416.3
|
1,245
|
1,900
|
1,275
|
486
|
594.4
|
601.1
|
482.7
|
P/E ratio
|
-4.1
x
|
-7.66
x
|
-10.3
x
|
-4.81
x
|
-5.99
x
|
-1.87
x
|
-3.75
x
|
82.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.48
x
|
7.02
x
|
8.35
x
|
6.37
x
|
4.65
x
|
2.15
x
|
1.51
x
|
1.07
x
|
EV / Revenue
|
2.37
x
|
6.28
x
|
8.35
x
|
6.01
x
|
3.35
x
|
2.65
x
|
1.87
x
|
1.07
x
|
EV / EBITDA
|
-3.56
x
|
-8.21
x
|
-14.1
x
|
-5.46
x
|
-1.39
x
|
-2.81
x
|
-7.53
x
|
-22.5
x
|
EV / FCF
|
-7.13
x
|
-25.1
x
|
-
|
-6.84
x
|
-1.73
x
|
-2.36
x
|
-5.91
x
|
-23.5
x
|
FCF Yield
|
-14%
|
-3.98%
|
-
|
-14.6%
|
-57.8%
|
-42.3%
|
-16.9%
|
-4.25%
|
Price to Book
|
-
|
-
|
-
|
-
|
3.33
x
|
64.8
x
|
-4.71
x
|
-
|
Nbr of stocks (in thousands)
|
42,958
|
51,052
|
61,226
|
64,174
|
75,146
|
76,129
|
-
|
-
|
Reference price
2 |
14.20
|
27.26
|
31.04
|
21.03
|
8.990
|
6.340
|
6.340
|
6.340
|
Announcement Date
|
2/24/20
|
3/1/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
175.3
|
198.3
|
227.5
|
212
|
145.2
|
224.6
|
320.7
|
449.5
|
EBITDA
1 |
-117
|
-151.6
|
-135.1
|
-233.5
|
-349.6
|
-211.5
|
-79.87
|
-21.44
|
EBIT
1 |
-137.4
|
-176.2
|
-161.8
|
-266.6
|
-388.1
|
-270.6
|
-174
|
5.674
|
Operating Margin
|
-78.34%
|
-88.83%
|
-71.11%
|
-125.73%
|
-267.24%
|
-120.46%
|
-54.25%
|
1.26%
|
Earnings before Tax (EBT)
1 |
-146.4
|
-188.8
|
-179.7
|
-278.2
|
-376.1
|
-268.9
|
-168.3
|
8.481
|
Net income
1 |
-146.4
|
-169.4
|
-180.1
|
-278.5
|
-111.4
|
-283.5
|
-148.4
|
-6.911
|
Net margin
|
-83.51%
|
-85.43%
|
-79.16%
|
-131.35%
|
-76.7%
|
-126.21%
|
-46.27%
|
-1.54%
|
EPS
2 |
-3.460
|
-3.560
|
-3.010
|
-4.370
|
-1.500
|
-3.384
|
-1.689
|
0.0767
|
Free Cash Flow
1 |
-58.41
|
-49.51
|
-
|
-186.5
|
-280.7
|
-251.5
|
-101.7
|
-20.5
|
FCF margin
|
-33.31%
|
-24.96%
|
-
|
-87.96%
|
-193.26%
|
-111.97%
|
-31.71%
|
-4.56%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
3/1/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
57.25
|
48.49
|
54.17
|
53.5
|
55.87
|
56.99
|
59.7
|
37.1
|
45.06
|
41.37
|
53.43
|
60.07
|
68.99
|
54.75
|
66.82
|
EBITDA
1 |
-40.13
|
-59.04
|
-57.34
|
-59.56
|
-57.55
|
-77.5
|
-
|
-86.99
|
-84.74
|
-129.4
|
-54.73
|
-43.62
|
-36.91
|
-
|
-
|
EBIT
1 |
-47.19
|
-66.13
|
-65.45
|
-68.13
|
-66.85
|
-87.05
|
-87.58
|
-92.58
|
-94.23
|
-139.2
|
-69.16
|
-54.05
|
-50.95
|
-49.6
|
-40.7
|
Operating Margin
|
-82.43%
|
-136.39%
|
-120.83%
|
-127.36%
|
-119.66%
|
-152.73%
|
-146.71%
|
-249.59%
|
-209.13%
|
-336.53%
|
-129.43%
|
-89.98%
|
-73.85%
|
-90.59%
|
-60.91%
|
Earnings before Tax (EBT)
1 |
-51.57
|
-75.92
|
-66.98
|
-69.51
|
-65.76
|
-86.25
|
-85.56
|
-89.23
|
-88.53
|
-135.8
|
-69.39
|
-53.83
|
-51.51
|
-49.6
|
-40.7
|
Net income
1 |
-51.57
|
-75.97
|
-67.03
|
-69.66
|
-65.82
|
-86.33
|
-85.63
|
150.7
|
-90.17
|
-136.1
|
-66.16
|
-52.11
|
-45.43
|
-49.06
|
-39.41
|
Net margin
|
-90.09%
|
-156.68%
|
-123.75%
|
-130.21%
|
-117.82%
|
-151.48%
|
-143.44%
|
406.35%
|
-200.12%
|
-328.86%
|
-123.81%
|
-86.75%
|
-65.85%
|
-89.59%
|
-58.97%
|
EPS
2 |
-0.8400
|
-1.200
|
-1.050
|
-1.090
|
-1.030
|
-1.270
|
-1.130
|
1.970
|
-1.180
|
-1.760
|
-0.8419
|
-0.6703
|
-0.5819
|
-0.5367
|
-0.4800
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
10/27/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/7/23
|
2/15/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
112
|
118
|
-
|
Net Cash position
1 |
194
|
146
|
-
|
74.7
|
190
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.5282
x
|
-1.483
x
|
-
|
Free Cash Flow
1 |
-58.4
|
-49.5
|
-
|
-186
|
-281
|
-252
|
-102
|
-20.5
|
ROE (net income / shareholders' equity)
|
-0.54%
|
-63.4%
|
-70.2%
|
-111%
|
-16.9%
|
-144%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-15.2%
|
-31.3%
|
-51.7%
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
731
|
905.2
|
286.8
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
2.700
|
0.1000
|
-1.350
|
-
|
Cash Flow per Share
2 |
-
|
-0.9000
|
-0.2500
|
-2.920
|
-3.770
|
-2.070
|
-0.6800
|
-
|
Capex
1 |
0.2
|
6.77
|
5.1
|
0.19
|
0.67
|
2.1
|
3.1
|
9
|
Capex / Sales
|
0.11%
|
3.41%
|
2.24%
|
0.09%
|
0.46%
|
0.93%
|
0.97%
|
2%
|
Announcement Date
|
2/24/20
|
3/1/21
|
2/24/22
|
2/23/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
6.34
USD Average target price
14.86
USD Spread / Average Target +134.34% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.48% | 483M | | +5.66% | 111B | | +11.23% | 105B | | -2.13% | 21.93B | | -12.15% | 22.34B | | -5.61% | 18.59B | | -36.52% | 18.12B | | -10.09% | 16.96B | | +3.33% | 13.7B | | +36.58% | 12.45B |
Bio Therapeutic Drugs
|